27 results on '"Ostojić-Kolonić, S"'
Search Results
2. W123 Micro RNAS expression profiling in myelodysplastic syndrome – Additional diagnostic method with future?
- Author
-
Mandac Rogulj, I., primary, Kardum Paro, M.M., additional, Martinović, M., additional, Kaić, G., additional, Šiftar, Z., additional, and Ostojić Kolonić, S., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Plazmablasti u urinu bolesnice sa plazmablastičnom varijantom multiplog mijeloma
- Author
-
Bendić, A., Radić-Krišto, D., Ostojić Kolonić, S., Planinc-Peraica, A., Vanke, M., Jelić-Puškarić, B., Milunović, V., Šušterčić, D., Kaić, G., Kardum-Skelin, I., and Anić, Branimir
- Subjects
plazmablasti ,urin ,multipli mijelom - Abstract
Uvod: Multipli mijelom je zloćudni tumor plazma stanica koji čini 10 do 15 % svih hematoloških bolesti. Dijagnoza se temelji na kombinaciji citopatoloških, radioloških i kliničkih karakteristika. Varijante multiplog mijeloma uključuju plazmablastičnu i pleomorfnu varijantu koje u dijelu slučajeva nastaju transformacijom klasičnog multiplog mijeloma i povezane su sa ekstramedularnim širenjem bolesti i lošijom prognozom. Prikaz slučaja: 71-godišnja boelsnia hospitalizriana je zbog obostrane lobarne pneumonije i pancitopenije.
- Published
- 2012
4. Schnitzlerov sindrom - prikaz slučaja
- Author
-
Janković, S, Ostojić Kolonić, S, Radić-Krišto, D, Jakšić, B, and Planinc-Peraica, A.
- Subjects
Schnitzlerov sindrom ,makroglobulinemija ,Schnizlerov sindrom - Abstract
Schnitzlerov sindrom je rijetki poremećaj obilježen kroničnom urtikarijom, rekurentnim febrilnim epizodama, limfadenopatijom i monoklonskom gamapatijom IgM ili Waldenstromovom makroglobulinemijom (WM). Opisujemo slučaj 74-godišnjeg bolesnika koji ima obilježja tog poremećaja. Tijekom godine dana imao je urtikarije sa inenzivnim svrbežom kože trupa, povremeno povišene temperature i bolove u lijevom ramenu i donjem dijelu leđa. Bolesnik ima hepatomegaliju, limfadenopatiju, ubrzanu SE, anemiju kronične bolesti, povišeni beta-2-mikroglobulin. Elektroforeza serumskih bjelančevina i imunoelektroforeza ukazale su na monoklonalni IgM i lake lance lambda u krvi. Citološkim nalazom i biopsijom koštane srži dijagnosticirana je WM. Fludarabin i medrol teško podnosi a i nakon toga ima epizode febriliteta. Nastavljeno je liječenje klorambucilom i medrolom intermitentno. U pauzama uzimanja medrola ponovno postaje febrilan. Tek nakon što je liječenje nastavljeno kontinuirano talidomidom i prednisolonom postaje afebrilan. Nakon 4-mjesečne terapije opaža se anemija značajnog stupnja koja se korigira transfuzijama koncentrata eritrocita. Primjena eritropoetina tijekom mjesec dana je bezuspješna. Ponovno učinjenim pretragama koštane srži potvrdi se dijagnoza WM sa elementima mijelodisplastičnog sindroma. Na Rtg kostiju opaža se izražena osteoporoza sa kompresivnom frakturom kralješka L2 nastale nakon pada. Klinička slika i morfološke pretrage ukazuju na Schnitzlerov sindrom koji je prvi put opisan 1972. godine. Do sada je objavljeno 50 bolesnika s tim sindormom. Naš bolesnik razlikuje se od prethodno objavljenih slučajeva po težini anemije i razvoju mijelodisplastičnog sindroma.
- Published
- 2007
5. Izražaj tkivnog sustava RAS u PH- MPS ovisi o mutacijskom statusu JAK2
- Author
-
Marušić Vrsalović, M, Pejša, V, Stoos Veić, T, Ostojić Kolonić, S, Ajduković, R, Hariš, V, Jakšić, O, and Kušec, R
- Subjects
_ - Abstract
_
- Published
- 2007
6. Preživljenje bolesnika s Hodgkinovom bolešću - iskustvo Odjela za Hematologiju KB Merkur
- Author
-
Ostojić Kolonić, S, Kalac, M, Ljubić, M, Planinc-Peraica, A, Jakšić, B, and Anić, Branimir
- Subjects
Hodgkinova bolest ,preživljenje ,_ - Abstract
CILJ: Prikazati ukupno preživljenje u bolesnika s Hodgkinovom bolešću liječenih u našem centru od kraja 1999. do lipnja 2004. godine. METODE: Analizirano je ukupno 72 bolesnika (medijan starosti 30 godine, raspon 15-80 godina), žene n=36 (50%), muškarci n=36 (50%)) kojima je postavljena dijagnoza Hodgkinove bolesti (limfocitna predominacija u 3 (4.2%), mješana celularnost u 31 (43%), klasični tip u 4 (5.6%) i nodularna skleroza u 34 (47.2%) bolesnika. REZULTATI: Bolesnici su u većini slučajeva liječeni kemoterapijom po shemi ABVD, ukupno njih 68 (94.4%), 1 (1.3%) je uz ABVD liječen i radioterapijom, 3 (4.2%) su liječena samo radioterapijom, a 1 (1.3%) je primio C-MOPP. Broj ciklusa ABVD terapije se kretao od 1 do 8, a većina je, uklupno 52 (76.5%) primila 6 ciklusa. Iz praćenja su izgubljena 4 (5.9%) bolesnika. Od preostalih 68, petero (7.4%) je umrlo nakon prosječno 19.4 mjeseca (medijan 15, raspon 13-33) od postavljanja dijagnoze. Među 63 bolesnika koji su na kraju praćenja bili živi 54 (79.6%) je bilo u kompletnoj remisiji, 4 (5.9%) su doživjela relaps nakon prosječno 32.2 mjeseca (raspon 23-49), parcijalnu remisiju su postigla 2 (2.9%), a troje (4.4%) je imalo primarno rezistentnu bolest. Vjerojatnost preživljenja 80 mjeseci nakon dijagnoze je 92.1% (muškarci 94%, žene 90.3%). ZAKLJUČAK: ABVD predstavlja optimalan kemoterapijski protokol za bolesnike s Hodgkinovom bolešću koji omogućuje iznimno dobre rezultate liječenja gledajući ukupno preživljenje.
- Published
- 2007
7. Klinička obilježja bolesnika i molekularna analiza onkogena IGH/MMSET - t(4 ; 14)(p16 ; q32) u multiplom mijelomu
- Author
-
Kušec, R, Livun, A, Marušić Vrsalović, M, Ostojić Kolonić, S, Hariš, V, Ajduković, R, Jakšić, O, and Pejša, V
- Subjects
_ - Abstract
_
- Published
- 2007
8. Dijagnostika i terapija limfoma u Hrvatskoj 2007. godine: gdje smo?
- Author
-
Ostojić Kolonić, S
- Subjects
_ - Abstract
_
- Published
- 2007
9. Radioimmunotherapy with Zevalin in Patients with Non-Hodgkin's Lymphoma
- Author
-
Huić, Dražen, Aurer, I, Žuvić, Marijan, Radman, I, Mitrović, Z, Ajduković, R, Sever-Prebilić, M, Ostojić-Kolonić, S, Škare-Librenjak, Lj, Labar, Boris, Dodig, Damir, and Padhy AK
- Subjects
radioimmunotherapy ,zevalin ,Non-Hodgkin's Lymphoma ,hemic and lymphatic diseases - Abstract
The aim of this prospective study was to asses the value of new radioimmunotherapy treatment with Zevalin (IgGl monoclonal antibody covalently bound to tiuxetan and labeled with Y-90) for adult patients with refractory or relapsed CD20+ follicular B-cell non- Hodgkin's lymphoma (NHL). This multicentric study included eight patients (median age 55 years, range 51 -59 years) from five hospitals in Croatia. The treatment involved a day 1 infusion of rituximab 250 mg /m2 ; a second infusion of rituximab on day 8, followed by "slow push" 10 minute infusion of Zevalin (median dose 1020 MBq ; range 820-1177 MBq). On follow-up 12 weeks after treatment response was achieved in six patients (75%). In three patients tumor mass was completely disappeared (complete response), and in other three patients tumor mass was significantly decreased (partial response). Hematological toxicity was observed in three patients and manifested with infections requiring hospitalization. One patient died because of extreme pancytopenia and Candida sepsis, in spite of support with granulocyte colony-stimulating factor. The median time to lowest blood counts was four weeks after Zevalin injection. Acute and non-hematological side-effects were not observed. Our preliminary results confirmed Zevalin as a very effective therapy for patients with refractory or relapsed CD20+ follicular B-cell NHL. One should be aware of hematologic toxicity ; therefore the close follow-up is required.
- Published
- 2007
10. Non-epithelial tumorsin aspiration cytology specimens of intra-abdominal organs and retroperitoneal nodes
- Author
-
Kardum-Skelin, I., Duter, D., Fabijani, I., Jeli-Pukari, B., Kušec, R., Kardum Paro, M.M., Planinc-Peraica, A., Ostojić Kolonić, S., Odak, D., Anić, P., Škegro, D., Voli-Cvrlje, V., and Kuleš, I. Papa, B. & Jakšić, B.
- Subjects
_ - Abstract
_
- Published
- 2004
11. IMMUNOPHENOTYPING OF FINE-NEEDLE ASPIRATES BY FLOW CYTOMETRY
- Author
-
Šiftar, Z., Kardum, M-M., Nazor, A., Bobetić-Vranić, T., Flegar-Meštrić, Z., Kardum-Skelin, I., Šušterčić, D., Minigo, H., Jakšić, B., Planinc- Peraica, A., Ostojić-Kolonić, S., Vrhovac, R., and Italian Society of Clinical Biochemistry
- Subjects
IMMUNOPHENOTYPING OF FINE-NEEDLE ASPIRATES - Abstract
Flow cytometry techniques (FCM) immunophenotyping, which can be readily performed on the limited size obtained by fine-needle aspirates (FNA), provides more objective information then FNA cytology alone. 87 lymph node FNA specimens from patients suspected having hematological malignancy were analyzed by FCM. Obtained results by FCM were interpreted according either to the normal values for lymph node lymphoid cells reported previously by Bryan et all (Ann. N.Y. Academ.Sci. 1993. 84: 404-406) or to the REAL classification of lymphoid neoplasms. Table 1 presents comparative results obtained by two methods on 87 lymph node FNA specimens: final diagnosisproved by: non-malignant hyperplasia malignant disorder: Hodgkin's disease B-chronic lymphocytic leukemia B-NonHodgkin lymphoma T-Non Hodgkin lymphoma FCM 36 48 0 3 36 6 cytology 36 51 3 3 37 8 agreement 100% 94% 0% 100% 97% 75% In conclusion, FCM is reliable and useful tools for distiguishing reactive and neoplastic processes, in asigment of malignant cells to the B or T cell lineage, even for futher subclassification of disease, but it is not diagnostically helpful in the case of Hodgkin's disease (without agreement with cytomorphology analyses).
- Published
- 1999
12. P041 Molecular detection and clinics of IgH/MMSET of t(4;14)(4p16;14q32) in multiple myeloma
- Author
-
Kusec, R., Livun, A., Marusic Vrsalovic, M., Ostojic Kolonic, S., Haris, V., Ajduković, R., Jaksic, O., and Pejsa, V.
- Published
- 2007
- Full Text
- View/download PDF
13. P034 Bone marrow renin-angiotensin system expression in polycythaemia vera and essential thrombocythaemia depends on JAK2 mutational status
- Author
-
Marusic Vrsalovic, M., Pejsa, V., Stoos Veic, T., Ostojic Kolonic, S., Ajduković, R., Haris, V., Jaksic, O., and Kusec, R.
- Published
- 2007
- Full Text
- View/download PDF
14. Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era-A Study of KroHem, the Croatian Group for Hematologic Diseases.
- Author
-
Aurer I, Jakšić O, Bašić-Kinda S, Mrđenović S, Ostojić-Kolonić S, Lozić D, Holik H, Novaković-Coha S, Berneš P, Krečak I, Morić-Perić M, Narančić M, Mitrović Z, and Valković T
- Abstract
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear whether this risk is affected by the choice of the antibody (rituximab vs. obinutuzumab). To elucidate the role of antineoplastic therapy on COVID-19 outcomes, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID-19 between October 2020 and April 2021. A total of 314 patients were identified, 75 untreated, 61 off treatment and 178 on treatment. The mortality rate in untreated and off-treatment patients was 15% and 16%; 9% and 10% had prolonged infection. In the on-treatment group, 3% were still prolonged positive at time of data collection, 62% recovered and 35% died; 42% had prolonged infection. Disease type, use of anti-CD20 monoclonal antibodies, prior autologous stem-cell transplantation (ASCT) and line of treatment did not significantly affect mortality. Mortality was higher in older patients ( p = 0.0078) and those treated with purine analogues ( p = 0.012). Prolonged COVID-19 was significantly more frequent in patients treated with anti-CD20 monoclonal antibodies ( p = 0.012), especially obinutuzumab, and purine analogues ( p = 0.012). Age, prior ASCT and treatment line did not significantly affect risk of prolonged infection. These data suggest that increased age and use of purine analogues are main risk factors for increased mortality of COVID-19 in patients with lymphoid malignancies. Obinutuzumab further increases the risk of prolonged disease, but not of death, in comparison to rituximab. Epidemiological considerations should be taken into account when choosing the appropriate antineoplastic therapy for patients with lymphoid malignancies.
- Published
- 2024
- Full Text
- View/download PDF
15. Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review.
- Author
-
Milunović V, Hude I, Rinčić G, Galušić D, Grubešić A, Martinović M, Popović N, Divošević S, Brčić K, Međugorac M, Kužat L, Strahija D, Mrđenović S, Mandac Smoljanović I, Radić-Krišto D, Gašparov S, Aurer I, and Ostojić Kolonić S
- Abstract
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiation, geriatric assessment should ideally be performed to address the patient's fitness and decide whether to pursue a curative or palliative approach. The ABVD regimen is poorly tolerated in unfit patients, with high treatment-related mortality. Alternative chemotherapy approaches have been explored, with mixed results obtained concerning their feasibility and toxicity in phase II trials. The introduction of brentuximab vedotin-based regimens led to a paradigm shift in first- and further-line treatment of elderly Hodgkin lymphoma patients, providing adequate disease control within a broader patient population. As far as checkpoint inhibitors are concerned, we are only just beginning to understand the role in the treatment of this population. In relapsed/refractory settings there are few options, ranging from autologous stem cell transplantation in selected patients to pembrolizumab, but unfortunately, palliative care is the most common modality. Importantly, published studies are frequently burdened with numerous biases (such as low numbers of patients, selection bias and lack of geriatric assessment), leading to low level of evidence. Furthermore, there are few ongoing studies on this topic. Thus, elderly Hodgkin lymphoma patients are hard to treat and represent an unmet need in hematologic oncology. In conclusion, treatment needs to be personalized and tailored on a case-by-case basis. In this article, we outline treatment options for elderly Hodgkin lymphoma patients.
- Published
- 2022
- Full Text
- View/download PDF
16. CD4+/CD57+/CD69+ T lymphocytes and CD14+ dendritic cells accumulate in advanced follicular lymphoma.
- Author
-
Gršković P, Hančić S, Dotlić S, Matulić M, Ostojić Kolonić S, Gašparov S, Dominis M, and Korać P
- Subjects
- CD4-Positive T-Lymphocytes metabolism, Dendritic Cells metabolism, Humans, Rituximab therapeutic use, Tumor Microenvironment, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
- Abstract
Follicular lymphoma is the second most frequent non-Hodgkin's lymphoma, accounting for around 20 % of all lymphomas in Western countries. Initially, it behaves indolently, but in time becomes more aggressive and less susceptible to chemotherapy. Multiple features correlate with the survival of the patients and the progression of the disease, such as therapy with rituximab, tumour microenvironment and the intrafollicular proliferation index. Our research was focused on the association of specific components of tumour microenvironment and the tumour behaviour. The presence and the relative percentage of T lymphocytes, follicular dendritic cells, dendritic cells and macrophages was detected by immunohistochemical staining of the antigens specific for certain cell populations. Our results show that T lymphocytes and dendritic cells affect tumour growth, possibly through interactions with tumour cells. Higher patients' ECOG score and the outcome of the disease are associated with the presence of CD14+ dendritic cells in tumour tissue, while the worse overall survival of patients is associated with the increased number of activated helper T lymphocytes that express marker of exhaustion CD57. Taken together, our results suggest that the efficiency of the immune response against follicular lymphoma depends on more than one type of immune cells. Also, we found that the phenotype of these cells, rather than just their number, affects the tumour behaviour and in consequence survival of the patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier GmbH. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
17. Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma.
- Author
-
Hančić S, Gršković P, Gašparov S, Ostojić Kolonić S, Dominis M, and Korać P
- Abstract
Hodgkin lymphoma (HL) is a biologically diverse group of lymphoid tumors, which accounts for 1% of all de novo neoplasms in the world's population. It is divided into two main groups: the more common classic Hodgkin lymphoma (cHL) and the less common nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). cHL is further divided into four subtypes, which differ in morphology and the contents of tumor microenvironment. Macrophages are one of the components of tumor microenvironment known to contribute to creating an immunosuppressive microenvironment, which inhibits the activity of cells expressing granzyme B against tumor cells, even when tumor cells are infected with Epstein-Barr virus (EBV). Our research aimed to explore the association between the specific contents of tumor microenvironment and the genetic anomalies in tumor cells. The presence and the relative percentage of cytotoxic T lymphocytes and macrophages was detected by immunohistochemical staining of the antigens specific for certain cell populations. Fluorescent in situ hybridization was used to detect anomalies in the genome of tumor cells and in situ hybridization was used to detect the presence of EBV. Our results show an association between the number of CD163+ macrophages and the number of TP53 copies or BCL6 gene translocation. Patients who had a higher number of CD163+ macrophages infiltrating tumor tissue and three or higher number of copies of TP53 showed poorer survival. We conclude that the presence of macrophages may contribute to genetic instability in cHL, which drives the progression of cHL and decreases survival of the patients.
- Published
- 2022
- Full Text
- View/download PDF
18. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
- Author
-
Milunović V, Mišura Jakobac K, Mandac Rogulj I, Martinović M, Radić-Krišto D, and Ostojić Kolonić S
- Subjects
- Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chlorambucil administration & dosage, Clinical Decision-Making, Combined Modality Therapy adverse effects, Combined Modality Therapy methods, Comorbidity, Diagnostic Imaging, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Molecular Targeted Therapy, Prognosis, Randomized Controlled Trials as Topic, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries occurring typically in elderly patients. These patients often present with comorbidities limiting treatment options. During the last decade, the treatment paradigm has rapidly changed with the introduction of novel oral targeted agents and monoclonal antibodies., Areas Covered: The review focuses on the combination of type II antiCD20 antibody obinutuzumab in combination with chemotherapy or oral targeted agents in patients not suited for fludarabine-based therapy because of comorbidities or age. The main focus of the review is whether classical immunochemotherapy with obinutuzumab-chlorambucil is still a valid therapeutic option or whether the combination of obinutuzumab and ibrutinib or venetoclax presents novel standard of care., Expert Opinion: Both pivotal and registrational studies iLLLUMINATE study testing the combination of ibrutinib and obinutuzumab and CLL14 study testing the fixed combination of venetoclax and obinutuzumab have shown major benefit over chemoimmunotherapy approach in this population. Furthermore, they have excellent activity in high-risk subgroups of CLL paving the road toward a chemo-free immunotherapy approach in this setting. However, there are some pitfalls in these strategies warranting further research.
- Published
- 2020
- Full Text
- View/download PDF
19. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
- Author
-
Milunović V, Mišura Jakobac K, Kursar M, Mandac Rogulj I, and Ostojić Kolonić S
- Subjects
- Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Brentuximab Vedotin administration & dosage, Brentuximab Vedotin adverse effects, Clinical Trials, Phase III as Topic, Drug Approval, Europe, Hodgkin Disease diagnosis, Hodgkin Disease etiology, Humans, Multicenter Studies as Topic, Neoplasm Metastasis, Neoplasm Staging, Randomized Controlled Trials as Topic, Treatment Outcome, United States, United States Food and Drug Administration, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brentuximab Vedotin therapeutic use, Hodgkin Disease drug therapy
- Abstract
ECHELON-1 study is a randomized open-labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow-up of 24.6 months, it has met its primary endpoint the reduction of modified progression-free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in-depth insight of pros and cons of this novel, promising but ultimately controversial regimen., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
20. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
- Author
-
Bogeljić Patekar M, Milunović V, Mišura Jakobac K, Perica D, Mandac Rogulj I, Kursar M, Planinc-Peraica A, and Ostojić Kolonić S
- Subjects
- Adult, Antineoplastic Agents, Alkylating pharmacology, Child, Humans, Medication Therapy Management, Bendamustine Hydrochloride pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, Non-Hodgkin drug therapy
- Abstract
- The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown efficacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fit patients, as defined in CLL10 study, B-R has yielded a more beneficial toxicity profile and its use in first line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.
- Published
- 2018
- Full Text
- View/download PDF
21. Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.
- Author
-
Jakšić B, Pejša V, Ostojić-Kolonić S, Kardum-Skelin I, Bašić-Kinda S, Coha B, Gverić-Krečak V, Vrhovac R, Jakšić O, Aurer I, Sinčić-Petričević J, Načinović-Duletić A, and Nemet D
- Subjects
- Combined Modality Therapy, Humans, Precision Medicine, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
Recent developments in the diagnosis and treatment of chronic lymphocytic leukemia (B-CLL) have led to change of approach in clinical practice. New treatments have been approved based on the results of randomized multicenter trials for first line and for salvage therapy, and the results of numerous ongoing clinical trials are permanently providing new answers and further refining of therapeutic strategies. This is paralleled by substantial increase in understanding the disease genetics due to major advances in the next generation sequencing (NGS) technology. We define current position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treatment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on new diagnostic stratification and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) and Bcl-2 antagonists. This is a rapidly evolving field as a great number of ongoing clinical trials con-stantly accumulate and provide new knowledge. We believe that novel therapy research including genomic diagnosis is likely to offer new options that will eventually lead to time limited therapies without chemotherapy and more effective clinical care for B-CLL based on individualized precision medicine.
- Published
- 2018
- Full Text
- View/download PDF
22. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
- Author
-
Milunović V, Bogeljić Patekar M, Jakubac KM, Mandac Rogulj I, Radić-Krišto D, Planinc-Peraica A, and Ostojić Kolonić S
- Subjects
- Humans, Lymphoma, Follicular pathology, Maintenance Chemotherapy, Antineoplastic Agents, Immunological therapeutic use, Lymphoma, Follicular drug therapy, Rituximab therapeutic use
- Abstract
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present data on the use of rituximab in the treatment of follicular lymphoma (FL). We will focus on rituximab maintenance strategies in the first and second line treatment. This approach has improved the outcome in FL patients with better progression-free survival in all patients and better overall survival in relapsed setting. Regardless of good results, this strategy has generated controversies in medical community in the range from the lack of overall survival benefit in first line setting, adverse effects of possible overtreatment and toxicities to its unknown role in the era of novel agents. The existing data suggest that rituximab maintenance should be a rational therapeutic option for all patients with FL responding to fi rst line therapy and transplant-ineligible patients responding to reinduction.
- Published
- 2017
- Full Text
- View/download PDF
23. [Lymphoma diagnosis and treatment - second Croatian consensus].
- Author
-
Aurer I, Gasparov S, Kralik M, Balenović A, Huić D, Santek F, Duletić-Nacinović A, Pejsa V, Ostojić-Kolonić S, and Grah JJ
- Subjects
- Humans, Lymphoma diagnosis, Lymphoma therapy
- Abstract
New, extended and modernized recommendations for diagnostics and treatment of lymphomas were accepted at a meeting held in March 2012 with the participation of major Croatian experts. They encompass morphological, radiological and nuclear diagnostics, systemic treatment, radiotherapy and follow-up of most tumors of lymphoid tissues occurring in adults. The recommendations were agreed upon by consensus. Reporters presented data and suggested recommendations which had been first discussed in working groups and then agreed upon on the plenary session.
- Published
- 2013
24. Myeloid sarcoma involving the breast.
- Author
-
Jelić-Puskarić B, Ostojić-Kolonić S, Planinc-Peraica A, Obad-Kovacević D, Kardum-Skelin I, and Jaksić B
- Subjects
- Adult, Anemia etiology, Anemia pathology, Biopsy, Fine-Needle, Bone Marrow pathology, Fatal Outcome, Female, Humans, Leukemia, Myeloid, Acute pathology, Leukocytosis etiology, Leukocytosis pathology, Recurrence, Thrombocytopenia etiology, Thrombocytopenia pathology, Breast Neoplasms pathology, Sarcoma, Myeloid pathology
- Abstract
Myeloid sarcoma is a tumor mass with extramedullary growth pattern, composed of myeloblasts or immature myeloid cells. The development of myeloid sarcoma may precede or concur with acute or chronic myeloid leukemia (AML or CML) or other myeloproliferative diseases or myelodysplastic syndromes (MDS). Isolated myeloid sarcoma of the breast is very rare. A case is presented of a 25-year-old, previously healthy woman that presented to our department for a palpable node, 5 x 2 cm in size, in the upper medial quadrant of her left breast. Fine needle aspiration (FNA) produced a sample consisting of medium sized blasts. Additional work-up revealed anemia, thrombocytopenia and leukocytosis, along with atypical blasts detected in peripheral blood and bone marrow smear. Based on the morphology, cytochemical characteristics and immature cell immunophenotype, it was considered a case of acute myeloid leukemia without maturation. In spite of intensive chemotherapy, the patient died within a year of diagnosis. In cases of isolated breast myeloid sarcoma, the diagnosis can be missed if the possibility of myeloid sarcoma is not remembered on differential diagnosis of a breast neoplasm.
- Published
- 2010
25. [The story about Hodgkin's lymphoma].
- Author
-
Ostojić Kolonić S
- Subjects
- Humans, Prognosis, Hodgkin Disease diagnosis, Hodgkin Disease pathology, Hodgkin Disease therapy
- Abstract
The exciting story about Hodgkin's lymphoma is 170 years old. Today, we know a lot about biology of this B cell neoplasma (derived from the germinative center), and the diagnostic standard criteria are clearly defined and accepted. Although the definition of prognostic factors for early disease varies between different study groups as well as the definition of advanced disease therapeutic aim is same for all clinicans: preserving the high cure rates while reducing the acute and long-term toxicities. Today, with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy followed by radiotherapy in some patients' group, more than 85% patients can be cured. Maybe, the recently published results of the latest researches in Hodgkin's lymphoma (evidence for the cancer stem cell; the role of T cells in tumour microenvironment in survival of lymphomas cells; the role of galectin-1 in tumor escape in Hodgkin's lymphoma) will help us to reach our therapeutic goal: cure for all patients with Hodgkin's lymphoma!
- Published
- 2008
26. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
- Author
-
Kardum-Skelin I, Planinc-Peraica A, Ostojić Kolonić S, Radić-Kristo D, Milas M, Vrhovac R, Sustercić D, Minigo H, and Jaksić B
- Subjects
- Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Prolymphocytic metabolism, Leukemia, Prolymphocytic mortality, Lymphoproliferative Disorders metabolism, Lymphoproliferative Disorders mortality, Male, Middle Aged, Prognosis, Survival Rate, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukemia, Prolymphocytic pathology, Lymphoproliferative Disorders pathology
- Abstract
Aim: The aim of the study was to identify the clinical and laboratory (hematologic, biochemical and morphological) prognostic parameters of chronic leukemic lymphoproliferative diseases (CLLPD)., Methods: The study included 155 CLLPD patients. Analysis was performed in the overall CLLPD population and separately in a subgroup of patients with B chronic lymphocytic leukemia with variants (B-CLL+V) including typical B chronic lymphocytic leukemia (B-CLL), mixed chronic lymphocytic leukemia and prolymphocytic leukemia (CLL/PLL), and a variant of chronic lymphocytic leukemia with lymphoplasmocytoid differentiation (CLL/IMC). Kaplan-Meier method (Statistica 7.1) was used on survival analysis., Results: Male patients older than 62 (p=0.03991), female patients (p=0.02871), patients not receiving antitumor therapy on study entry (p=0.01902) and patients not treated for CLLPB upon study entry (p=0.04076) showed better survival rate. Older patient predominated in the group requiring no antitumor therapy (p=0.019247). Analyis of sex distribution yielded an equal male to female ratio in the overall CLLPD population and B-CLL+V subgroup. Mann-Whitney U-test was used to assess the clinical significance of quantitative parameters related to patient age and sex. The level of bilirubin, the size of cervical lymph nodes and doubling of peripheral blood lymphocytosis (DTL) were lower in the group of older patients (>60 years). Men had higher levels of hemoglobin, bilirubin, SGOT and creatinine, and larger spleen and liver. Statistically significant survival differences were recorded for 16 of 20 clinical parameters. Patients older than 60, female patients and patients receiving no antitumor therapy showed better survival. Lower clinical stage according to Rai and Binet and total tumor mass (TTM) lower than 9 indicated better prognosis, whereas patients with spleen enlargement and multiple regions involved with lymph node enlargement showed poorer survival. B-CLL+V patients and patients free from doubling of total tumor (DTM) or of absolute lymphocyte count (DTL) within 12 months had better survival than the overall CLLPD patient population. A statistically significant survival difference was recorded for 5 of 15 bone marrow (BM) parameters tested: normal and less cellular BM puncture specimen, >70% of all lymphatic cells, >16% of atypical lymphatic cells, and >18% of granulocytes in myelogram indicated better prognosis. Poorer disease outcome was associated with interstitial and nodular infiltration found on bone biopsy. Ten of 20 hematologic parameters were found to be statistically significant. Poorer prognosis was associated with red blood cell count <2.5 x 10(12)/L, leukocyte count >100 x 10(9)/L, reticulocyte count >5/10(3) E, hemoglobin <100 g/L and iron <15 mol/L. Better survival was associated with absolute count of total lymphatic cells <100 x 10(9)/L and absolute count of atypical lymphatic cells <5 x 10(9)/L in peripheral blood; <10% of all atypical lymphatic cells, >5.1% monocytes and >10.1% granulocytes in differential blood count. Statistically significant survival differences were found for 10 of 20 biochemical parameters tested. Poorer survival was recorded in patients with LDH >300 U/L, SGOT >24 U/L, calcium <2.3 mmol/L, total protein <66.1 g/L, albumin <40 g/L, alpha2 globulin<5.9 g/L, beta globulin <7.3 g/L, y globulin <9 g/L and IgG <10 g/L. Better prognosis was only indicated by lower levels of IgM (<0.91 g/L)., Conclusion: Careful clinical examination is an important step on assessing the extent and progression of the disease, and a major chain on tailoring individualized therapeutic approach, along with clinical stages according to Rai and Binet, CLLPD subtype and progression factors (DTM and DTL). Laboratory parameters (hematologic and biochemical) as objective quantitative parameters obtained by simple venipuncture, in contrast to the 'researcher-dependent' ones, increase the utilization of some of these parameters as risk factors in CLL.
- Published
- 2008
27. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
- Author
-
Aurer I, Huić D, Zuvić M, Sever-Prebilić M, Ajduković R, Radman I, Skare-Librenjak L, Ostojić-Kolonić S, and Labar B
- Subjects
- Adult, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Murine-Derived, Antigens, CD20 immunology, Drug Resistance, Female, Humans, Lymphoma, B-Cell radiotherapy, Lymphoma, Follicular drug therapy, Male, Middle Aged, Recurrence, Rituximab, Yttrium Radioisotopes adverse effects, Antibodies, Monoclonal therapeutic use, Lymphoma, Follicular radiotherapy, Yttrium Radioisotopes therapeutic use
- Abstract
Radioimmunotherapy is a new antineoplastic treatment modality combining the effects of irradiation and monoclonal antibodies. 90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of yttrium is attached, used for treating follicular lymphomas (FL). Using this compound we treated 8 patients with FL relapsing or refractory to combinations of rituximab and chemotherapy. Severe neutropenia developed in 5, and severe thrombocytopenia and anemia in 3 patients. Serious infections developed in 2 patients, one died. Six patients responded to treatment, 4 are still in remission after a median follow-up of 15 months, 2 died of lymphoma. Best response was achieved in low-risk patients with a low tumor burden. 90Y-ibritumomab tiuxetan is an effective treatment for FL with significant hematological toxicity and a high price.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.